Power Law company profile

Turnstone Biologics

Biotech & Life Sciences · San Francisco, United States · Founded 2015 · IPO 2023 Thoroughbred

Driving innate and adaptive tumor immunity to provide benefit to cancer patients underserved by current treatments

Headcount

<100

Current team size

Unlock exact value

Featured in $10B+ revenueThoroughbred · Power Law outcome

Investors

16 investors on Turnstone Biologics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage

Versant Ventures

Series B+ 15 investors entered at this stage

CaaS Capital Management

404 Bio

Northleaf

Surveyor Capital

Point72

F-Prime

FACIT.com

Takeda Ventures

Ridgeback Capital

Eventide Asset Management

OrbiMed

PFM Health Sciences

Point72 Ventures

Eight Roads Ventures

JM Family Enterprises

Global footprint

Where Turnstone Biologics has talent and traffic

AI talent share

4.0% of workforce is AI talent
(1 of 25 staff)

Core AI00%

Other AI14%

Non-AI workforce2496%

Workforce by country

🇺🇸 United States · San Francisco HQ

Book a demo for the full country breakdown

Web traffic by country

1.3K monthly visits
across markets

🇺🇸 United States84.6%

🇯🇵 Japan15.4%

🇮🇹 Italy0%

Top 3 markets shown

Market sentiment

What the market is saying about Turnstone Biologics

An AI-synthesized read of the highest-engagement posts about Turnstone Biologics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Turnstone Biologics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles